drugset
drugset / Trial / NCT04067947

Phase 1 Pharmacokinetics, Safety, and Tolerability Study

NCT04067947 ↗

Phase 1 Completed 64 enrolled Xgene Pharmaceutical Group
RandomizedSequentialTriple-blindBasic science

Summary

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Oral Dose Study of the Pharmacokinetics, Safety, and Tolerability of XG005 in Healthy Volunteers.

Timeline

Start
2019-07-08
Primary completion
2019-12-03
Completion
2020-02-10

Drugs

EvaluationDrugModalityDoseRoute
Subject XG005 Unknown — Oral

Indications

No indication recorded.